Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of aloperine (ALO) as medicine used for treating cerebral arterial thrombosis

A technology for ischemic stroke and ischemic stroke, which is applied in the application field of aloperine as a drug for treating ischemic stroke, so as to improve antioxidant capacity, reduce the increase of calcium ion concentration, and reduce the rate of apoptosis Effect

Active Publication Date: 2015-04-08
NINGXIA MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have found that aloperine has anti-inflammatory and anti-cancer effects, but its protective effect on neurological damage diseases such as cerebral ischemic nerve injury and neurodegenerative diseases has not been reported so far, and it will develop into ischemic stroke Therapeutic drugs have extremely high potential value and social significance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of aloperine (ALO) as medicine used for treating cerebral arterial thrombosis
  • Application of aloperine (ALO) as medicine used for treating cerebral arterial thrombosis
  • Application of aloperine (ALO) as medicine used for treating cerebral arterial thrombosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] The use of aloperine as a medicine for treating ischemic stroke, wherein the molecular structural formula of aloperine is shown in formula (1)

[0022]

[0023] Ischemic stroke is ischemic stroke in the acute phase or in the recovery phase. The single application dose of aloperine in the cells is 25 mg / L, and the dosage form of the drug is a powder injection dosage form permitted by pharmacy.

Embodiment 2

[0025] The use of aloperine as a medicine for treating ischemic stroke, wherein the molecular structural formula of aloperine is shown in formula (1)

[0026]

[0027] The ischemic stroke is ischemic stroke in the acute phase or repairing phase, the single application dose of aloperine in the cells is 50mg / L, and the dosage form of the drug is an injection dosage form allowed by pharmacy.

Embodiment 3

[0029] Aloperine is used as a drug for the treatment of ischemic stroke, and its molecular structural formula is as shown in formula (1)

[0030]

[0031] The ischemic stroke is ischemic stroke in the acute phase or repairing phase, the single application dose of aloperine in the cells is 100 mg / L, and the dosage form of the drug is an oral dosage form permitted by pharmacy.

[0032] The effect of embodiment 1 to 3 can be verified by following animal experiments:

[0033] 1 Experimental materials

[0034] Cultured neonatal rat hippocampal neurons, methazolium blue (MTT) was purchased from Guangzhou Chemical Reagent Factory; microplate reader was purchased from Thermo Company; lactate dehydrogenase LDH, malondialdehyde MDA, catalase CAT, TAOC , superoxide dismutase SOD, glutathione peroxidase GSH-PX, ROS assay kit: product of Nanjing Jiancheng Bioengineering Institute; calcium ion, Hoechst, MMP kit: Biyuntian Reagent Company.

[0035] 2 Experimental methods

[0036] 2.1 T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of aloperine (ALO) as a medicine used for treating cerebral arterial thrombosis. An oxygen and glucose deprivation model is built, and a protective effect of ALO to neonatal rat brain ischemia after oxygen and glucose deprivation and a possible mechanism are studied; results show that active oxygen and malonaldehyde contents in cells are reduced after oxygen and glucose deprivation and reperfusion, the contents of three antioxidant enzymes, namely catalase, superoxide dismutase and glutathion peroxidase, are increased, and the total antioxidant capacity is improved; besides, ALO can be used for stabilizing the mitochondrial membrane potential and reducing the apoptosis rate of a hippocampal neuron and calcium ion concentration, so that the protective effect of ALO can be related to oxidation resistance. Therefore, ALO has a protective effect on ischemic injury.

Description

technical field [0001] The invention relates to the application of aloperine, in particular to the application of aloperine as a medicine for treating ischemic stroke. Background technique [0002] Ischemic brain disease, also known as ischemic stroke, has become one of the major fatal and disabling diseases worldwide, seriously threatening human life and health. Studies in recent years have found that a considerable part of the blood vessels after cerebral ischemia can recanalize naturally or recover after thrombolytic therapy, but it is followed by further brain damage and dysfunction, that is, ischemic recanalization. Therefore, inhibiting ischemia-reperfusion injury has become a key link in the treatment of ischemic encephalopathy. [0003] Research on the mechanism of cerebral ischemia-reperfusion injury has progressed rapidly in recent years. It is believed that brain cell injury caused by interruption of cerebral blood flow and reperfusion is a multi-factor, multi-me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4748A61P9/10
CPCA61K31/4748
Inventor 余建强马宁田周茹李玉香郝银菊李男杨文莉刘河涛
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com